Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Evaluating the Effectiveness of Cognitive Rehabilitation on Everyday Memory in Multiple Sclerosis Patients Publisher Pubmed



Mousavi S1 ; Zare H1 ; Etemadifar M2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Psychology, Payame Noor University, Tehran, Iran
  2. 2. Department of Neurology Medical School, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Neuropsychological Rehabilitation Published:2020


Abstract

The aim was to determine the effectiveness of cognitive rehabilitation for everyday memory function in patients with multiple sclerosis. A total of 60 multiple sclerosis patients with cognitive impairment were randomly assigned to three groups, experimental, placebo and control. The groups were well matched in baseline characteristics. Everyday memory was assessed at baseline immediately post-intervention (8 weeks) and five weeks post-intervention. The experimental group received cognitive rehabilitation programme in 1-hour sessions on a weekly basis for 8 weeks. The placebo group received relaxation techniques on a weekly basis for eight weeks and the control group received no intervention. The results indicated that a cognitive rehabilitation programme had a positive effect on the everyday memory of patients in the experimental group post-intervention. However, there was no significant effect of intervention 5 weeks post-intervention. The present study demonstrated that cognitive rehabilitation had a positive effect on the everyday function of the multiple sclerosis patients. However, the effect did not last and that everyday memory function returned to its pre-intervention level. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
Other Related Docs
25. Category-Semantic Memory Deficit in Multiple Sclerosis, Tehran University Medical Journal (2009)
46. Comparison of Fingolimod, Dimethyl Fumarate and Teriflunomide for Multiple Sclerosis, Journal of Neurology, Neurosurgery and Psychiatry (2019)